|
The patient was treated as part of the mimics 3d usa post-market observational study.On the (b)(6) 22, the patient was implanted with one biomimics 3d stent (a 6 x 100mm stent) to treat a denovo lesion of the superficial femoral artery (sfa) middle third to distal third segment in the left leg.A contralateral approach was used.The lesion was also post-dilated with percutaneous transluminal angioplasty (pta).The site reported that on (b)(6) 22, an event of restenosis of treated segment (target lesion) was identified.The patient who has a medical history of chronic neuropathy, attended the clinic with complaints of left lower extremity discomfort.The patient had a duplex ultrasound (dus) of bilateral lower extremities.The target limb (left leg extremity (lle)) showed > 75% stenosis.It was reported as target lesion related.It was reported as definitely related to the device.The patient was treated on (b)(6) 22 with drug coated balloon / drug eluting balloon (dcb/deb) and laser atherectomy on the sfa middle third to distal third segment.This was reported as a target lesion revascularisation(tlr)/target vessel revascularisation (tvr).The event was reported as resolved/recovered and the device remains implanted.
|
|
There was no reported device malfunction and the device was not returned for analysis.A review has been performed of the manufacturing certificate of conformance associated with this lot.There were no non-conformances or deviations which could be associated with this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effects of restenosis leading to intervention/leg pain are listed in the biomimics 3d instructions for use and are known patient effects of peripheral stenting procedures.There is no indication of a product quality issue with respect to the design, manufacture or labelling of the device.If further information regarding this event becomes available, a follow-up report will be submitted.
|